Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Structure-Affinity Relationships and Structure-Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists.

Xia L, Burger WAC, van Veldhoven JPD, Kuiper BJ, van Duijl TT, Lenselink EB, Paasman E, Heitman LH, IJzerman AP.

J Med Chem. 2017 Sep 14;60(17):7555-7568. doi: 10.1021/acs.jmedchem.7b00950. Epub 2017 Aug 30.

PMID:
28806076
2.

Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields.

Varani K, Vincenzi F, Ravani A, Pasquini S, Merighi S, Gessi S, Setti S, Cadossi M, Borea PA, Cadossi R.

Mediators Inflamm. 2017;2017:2740963. doi: 10.1155/2017/2740963. Epub 2017 Feb 1. Review.

3.

The Adenosinergic System in Diabetic Retinopathy.

Vindeirinho J, Santiago AR, Cavadas C, Ambrósio AF, Santos PF.

J Diabetes Res. 2016;2016:4270301. doi: 10.1155/2016/4270301. Epub 2016 Feb 29. Review.

4.

Adenosine A3 Receptor: A promising therapeutic target in cardiovascular disease.

Nishat S, Khan LA, Ansari ZM, Basir SF.

Curr Cardiol Rev. 2016;12(1):18-26. Review.

5.

Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor.

Haeusler D, Grassinger L, Fuchshuber F, Hörleinsberger WJ, Höftberger R, Leisser I, Girschele F, Shanab K, Spreitzer H, Gerdenitsch W, Hacker M, Wadsak W, Mitterhauser M.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):928-39. doi: 10.1007/s00259-014-2985-2. Epub 2015 Mar 5.

6.

Anti-inflammatory effects of adenosine N1-oxide.

Kohno K, Ohashi E, Sano O, Kusano H, Kunikata T, Arai N, Hanaya T, Kawata T, Nishimoto T, Fukuda S.

J Inflamm (Lond). 2015 Jan 20;12(1):2. doi: 10.1186/s12950-014-0045-0. eCollection 2015.

7.

Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.

Daniele S, Zappelli E, Natali L, Martini C, Trincavelli ML.

Cell Death Dis. 2014 Nov 27;5:e1539. doi: 10.1038/cddis.2014.487.

8.

Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.

Vadlapudi AD, Patel A, Cholkar K, Mitra AK.

Recent Pat Biomed Eng. 2012 Apr 1;5(1):83-101.

9.

Effect of adenosine on melanogenesis in b16 cells and zebrafish.

Kim MY, Lee HE, Im M, Lee Y, Kim CD, Lee JH, Seo YJ.

Ann Dermatol. 2014 Apr;26(2):209-13. doi: 10.5021/ad.2014.26.2.209. Epub 2014 Apr 30.

10.

Activation of adenosine A3 receptor alleviates TNF-α-induced inflammation through inhibition of the NF-κB signaling pathway in human colonic epithelial cells.

Ren T, Qiu Y, Wu W, Feng X, Ye S, Wang Z, Tian T, He Y, Yu C, Zhou Y.

Mediators Inflamm. 2014;2014:818251. doi: 10.1155/2014/818251. Epub 2014 Apr 22.

11.

Potential for developing purinergic drugs for gastrointestinal diseases.

Ochoa-Cortes F, Liñán-Rico A, Jacobson KA, Christofi FL.

Inflamm Bowel Dis. 2014 Jul;20(7):1259-87. doi: 10.1097/MIB.0000000000000047. Review.

12.

Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Burnstock G.

Purinergic Signal. 2014 Mar;10(1):3-50. doi: 10.1007/s11302-013-9397-9. Epub 2013 Dec 4. Review.

13.

Pulsed electromagnetic fields increased the anti-inflammatory effect of A₂A and A₃ adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts.

Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R, Goldring MB, Borea PA, Varani K.

PLoS One. 2013 May 31;8(5):e65561. doi: 10.1371/journal.pone.0065561. Print 2013.

14.

Inosine induces presynaptic inhibition of acetylcholine release by activation of A3 adenosine receptors at the mouse neuromuscular junction.

Cinalli AR, Guarracino JF, Fernandez V, Roquel LI, Losavio AS.

Br J Pharmacol. 2013 Aug;169(8):1810-23. doi: 10.1111/bph.12262.

15.

Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.

Jacobson KA.

J Med Chem. 2013 May 23;56(10):3749-67. doi: 10.1021/jm400422s. Epub 2013 May 9. Review.

16.

Adenosine A3 receptor activation attenuates lung ischemia-reperfusion injury.

Mulloy DP, Sharma AK, Fernandez LG, Zhao Y, Lau CL, Kron IL, Laubach VE.

Ann Thorac Surg. 2013 May;95(5):1762-7. doi: 10.1016/j.athoracsur.2013.01.059. Epub 2013 Mar 28.

17.

Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor.

Kozma E, Gizewski ET, Tosh DK, Squarcialupi L, Auchampach JA, Jacobson KA.

Biochem Pharmacol. 2013 Apr 15;85(8):1171-81. doi: 10.1016/j.bcp.2013.01.021. Epub 2013 Jan 31.

18.

The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells.

Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R, Borea PA, Varani K.

PLoS One. 2012;7(6):e39317. doi: 10.1371/journal.pone.0039317. Epub 2012 Jun 25.

19.

Mast cell adenosine receptors function: a focus on the a3 adenosine receptor and inflammation.

Rudich N, Ravid K, Sagi-Eisenberg R.

Front Immunol. 2012 Jun 4;3:134. doi: 10.3389/fimmu.2012.00134. eCollection 2012.

20.

Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.

Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA, Jacobson KA.

J Med Chem. 2012 May 24;55(10):4847-60. doi: 10.1021/jm300396n. Epub 2012 May 16.

Supplemental Content

Support Center